

Research Article

Is the Occurrence or Reversal of Nonalcoholic Fatty Liver Disease Associated with Long-Term *Helicobacter pylori* Infection among Chinese Adults? A Cohort Study

Xia-Xia Zhao,¹ Rui-Ling Wang ,² Ming-Hao Liu,² and Xiao-jun Huang ¹

¹Department of Gastroenterology, Lanzhou University Second Hospital, No. 82 Cuiying Men, Cheng Guan District, Lanzhou, 730030 Gansu Province, China

²The PLA Rocket Force Characteristic Medical Center, Digestive Internal Medicine, Beijing, China

Correspondence should be addressed to Xiao-jun Huang; huangxj@lzu.edu.cn

Received 9 December 2020; Accepted 22 October 2021; Published 24 November 2021

Academic Editor: Chiara Ricci

Copyright © 2021 Xia-Xia Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Previous studies have suggested a link between *Helicobacter pylori* (*H. pylori*) infection and nonalcoholic fatty liver disease (NAFLD), yet long-term follow-up studies to elucidate this association are lacking. We aimed to identify the relationship between NAFLD and *H. pylori* in these people. **Methods.** A total of 2,934 adults between June 2013 and October 2017 were collected; among them, 675 people met the requirements. People were assessed for *H. pylori* infection diagnosis as detected by the carbon-13 urea breath test; they were also assessed for NAFLD diagnosis by ultrasound. **Results.** *H. pylori* infection was present in 206 patients (30.5%), and 469 (69.5%) participants were classified as controls. Participants with *H. pylori* infection had a higher rate of incident NAFLD than those who were uninfected (37/206; 18% versus 73/469; 15.6%) ($p < 0.001$). Compared with the control group, the recovery rate of NAFLD in the *H. pylori*+ve group was low (6/206, 2.9% versus 33/469, 7.0%) ($p < 0.001$). Besides, the incidence of uric acid, postprandial blood glucose, TG, LDL-C, HDL-C, and fasting plasma glucose was significantly different between the two groups ($p < 0.001$), but no difference was found in alanine aminotransferase (ALT), liver-total protein, urea nitrogen, and cholesterol ($p > 0.05$). **Conclusion.** *H. pylori* infection was a risk factor for NAFLD and affected the occurrence or reversal of NAFLD, indicating that *H. pylori* infection eradication might play a role in reducing the risk of NAFLD.

1. Introduction

Helicobacter pylori (*H. pylori*) is a gram-negative bacterium. There are approximately 4.4 billion individuals diagnosed with *H. pylori*+ve worldwide; the infection exhibits a high estimated global prevalence; its current average prevalence is assessed to be about 58% (varying from 39.9% to 91.7%) [1, 2]. In China, about half of the population are infected with *H. pylori* [3–5]. *H. pylori* infection usually happens in the early phase of life and persists throughout the host's life if untreated [4]. Clinical manifestations of *H. pylori* infection include peptic ulcer disease, gastric mucosa-associated lymphoid tissue, noncardiac gastric adenocarcinoma, and

even stomach cancer [5]. Notably, *H. pylori* infection not only affects the stomach but is linked to several extragastric diseases.

There is evidence supporting the association of *H. pylori* infection with NAFLD. Similarly to the high prevalence of nonalcoholic fatty liver disease (NAFLD) [6, 7], hepatosteatosis is defined as the fat accumulation of at least 5% of liver weight. Without excess alcohol intake, this condition is called nonalcoholic fatty liver disease (NAFLD), with a prevalence ranging from 17% to 33% in European countries such as the UK and about 4% to 25% in China [8, 9], being even higher in specific populations, e.g., patients with type 2 diabetes mellitus (T2DM) or obesity [7]. The natural history

of NAFLD ranges from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH) with or without fibrosis, which may progress to cirrhosis and hepatocellular carcinoma [6]. Studies have shown that *H. pylori* infection has been associated with increased levels of proinflammatory cytokines and IR. Evidence suggests that *H. pylori* are involved in the regulation of gastric hormones leptin and ghrelin that affect insulin sensitivity and adiposity [10]. Another study from India has revealed a higher prevalence of *H. pylori* infection in diabetes than controls [11]. The systemic impact of *H. pylori* infection has received increasing attention [10, 12]. Recent data suggest a possible role of *H. pylori* in the pathogenesis of NAFLD [13]. Other studies have reported that *H. pylori* infection may be an important risk factor for NAFLD [14–17]; additionally, our previous study indicated similar results [18]. However, previous studies have not consistently observed the effects of *H. pylori* on NAFLD in the long term in China. Long-time cohort studies are needed to elucidate the association between *H. pylori* infection and NAFLD. If proven to be a significant risk factor for NAFLD, *H. pylori* infection has therapeutic potential, as it can be eradicated in most patients.

The incidences of NAFLD are rapidly increasing, leading to increased clinical and economic burdens [19]. Identifying risk factors with potential therapeutic implications is important in managing NAFLD and decreasing these burdens. In this study, we collected the five-year physical examination indexes of participants who visited our hospital to explore *H. pylori* infection's effects on NAFLD.

2. Materials and Methods

2.1. Statement of Ethics. This is a retrospective cohort study. Patients consented to the charts' review, and their information was not disclosed outside our team. Our research was in line with the Helsinki declaration's ethical guidelines (as revised in Brazil 2013), as reflected in the prior approval of our agency's human research council.

2.2. Inclusion and Exclusion Criteria. Inclusion criteria were complete, having not used proton pump inhibitors (PPIs), histamine type 2 receptor antagonists (H2A), antibiotics, bismuth, or sucralfate for up to one month before the ¹³C-UBT (carbon-13 urea breath test).

Individuals who had received complete eradication of *H. pylori*, antibiotics, chronic liver disease, or cirrhosis were excluded. Other exclusion criteria include a self-reported history of malignancy; positive serologic markers for hepatitis B virus; the history of alcohol overconsumption (<210 g per week in men and <140 g per week in women during the past 12 months); and no long-term history of taking steatogenic medications, i.e., amiodarone, methotrexate, tamoxifen, and glucocorticoids. Exclusion of diseases can lead to the fatty liver such as genotype 3 HCV infection, Wilson's disease, autoimmune hepatitis, total parenteral nutrition, hypo- β -lipoproteinemia, congenital lipodystrophy, and celiac disease. Participants with missing data on important covariates were excluded.

2.3. Study Population. This study included healthy adults, aged 20 years or older, who participated in a comprehensive health screening exam at the General Hospital of PLA Rocket Force from June 2013 to October 2017. Since our objective was to evaluate the longitudinal association between *H. pylori* infection and NAFLD, we included subjects who underwent screening exams every year, including abdominal ultrasonography (US), to assess the fatty liver status and establish the baseline of *H. pylori* infection status. About 2,934 people coming to our hospital for physical examination every year were asked to take blood tests, abdominal ultrasonography (US), and complete ¹³C-UBT to diagnose active *H. pylori* infection. Biochemical investigation, including ALT, total protein, albumin, cholesterol, TG, HDL-C, LDL-C, urea nitrogen, uric acid, fasting plasma glucose, and postprandial blood sugar, was performed in all individuals. After a 12 h overnight fast, 15 mL of blood was collected from the antecubital vein. It was analyzed within 4 hours after collection for biochemistry tests. After an overnight fast, ¹³C-UBT was performed using the Proto Pylori kit (Isodiagnostika Canada), containing 75 mg of ¹³C-UBT and additives. Two breath samples were collected within a 30-minute interval. Patient samples were analyzed by gas chromatography. The results were expressed as delta over baseline (DOB). NAFLD was examined using a Philips HD 11 XE multifunction color Doppler diagnostic instrument, according to the new standard criteria for NAFLD by China, 2018 [19]. The same ultrasound physician performed all ultrasound measurements throughout the study. The diagnostic criteria are as follows: ALT > 40 U/L, total protein > 5.69 mmol/L, cholesterol > 5.69 mmol/L, TG > 1.7 mmol/L, HDL - C < 1.7 mmol/L, LDL - C > 3.64 mmol/L, urea nitrogen > 8.05 mmol/L, creatinine > 115 mmol/L, uric acid > 416 mol/L, fasting plasma glucose > 6.1 mmol/L, and postprandial plasma glucose > 7.8 mmol/L. The results of ¹³C-UBT are expressed as DOB values; DOB \geq 4 was *H. pylori* +ve, and DOB < 4 was *H. pylori*-ve. NAFLD and Mets were diagnosed according to the latest guidelines [19, 20]. Since the same people have physical examinations in our hospital every year, we have the opportunity to collect and identify their data over a long period of time.

2.4. Statistical Analysis. SPSS software version 22.0 (SPSS Inc., Chicago, IL) was used for statistical analysis. The Student *t*-test and chi-square test were used to analyze the distribution of continuous variables and classified variables. The data are represented as the mean \pm standard deviation, and *p* < 0.05 was considered statistically significant.

3. Results

3.1. Data Collection. A total of 2,934 participants were collected. People who did not meet the inclusion criteria were removed (*n* = 1,816), the remaining 1,118 people were included, and among them, additional 40 people were excluded due to the ¹³C-UBT standard which is not followed; eventually, 1,078 people were left and had completed the ¹³C-UBT for 5-year follow-up. After excluding the participants (*n* = 403) who did not complete ¹³C-UBT

for 5 years, in total, 675 (males/females: 506/169; aged 54.7 ± 8.6 years) subjects who met these criteria were selected. The further screening revealed 206 individuals with $\text{DOB} \geq 4$ and 469 people with $\text{DOB} < 4$, and the specific groups are shown in Figure 1. Characteristics of all individuals are presented in Table 1, the continuous prevalence of *H. pylori* positivity was found to be 30.5% for 5 years (206/675), and the infection rate of *H. pylori* gradually decreased from 2013 to 2017 (Figure 2); NAFLD was found to be 31.9% (110/675).

3.2. General Characteristics of *H. pylori* Infection. The characteristics classified being *H. pylori*+ve or *H. pylori*-ve are shown in Table 2. In this study, participants with NAFLD had a higher rate of *H. pylori* infection than those without NAFLD (27/206; 18% versus 73/469; 15.6%). When *H. pylori*+ve and *H. pylori*-ve individuals were compared, postprandial blood sugar (17/206; 8.3% versus 30/469; 6.4%), HDL-C (14/206; 6.8% versus 16/469; 3.4%), and uric acid (14/206; 6.8% versus 20/469; 4.3%) were found to be significantly higher in *H. pylori*+ve patients. Additionally, we could clearly find that the prevalence of LDL-C in the group with and without *H. pylori* was 106 patients (51.5%) and 235 patients (50.1%), in which this difference was significant, fasting plasma glucose, in this cohort, also showed a statistically significant difference ($p < 0.001$). According to the TG levels, there was a significant difference in the two groups (20/206; 9.7% versus 39/469; 8.3%), while no difference was found between the two groups in terms of ALT (0.518), total protein (0.087), urea nitrogen (0.518), and cholesterol (0.497). Also, both groups predominantly consisted of males, while the ratio of males in the *H. pylori*+ve group (152/206; 73.7%) was lower than that in the control group (354/469; 75.4%) ($p = 0.026$).

3.3. Annual NAFLD Based on *H. pylori* Status. In separate annual observational studies, there were about 2,934 individuals; among them, those who were not tested for ^{13}C -UBT were excluded. Finally, the status of *H. pylori* infection in the population from June 2013 to October 2017 was shown as follows: 752/1,718 (43.7%), 750/1,951 (38.4%), 643/1,895 (33.9%), 589/1,867 (31.5%), and 589/1,927 (30.6%) (Figure 3). The prevalence of NAFLD in the group with and without *H. pylori* has statistically significant differences every year ($p < 0.01$) (Figure 3).

3.4. The Relationship between the Occurrence and Recovery of NAFLD and *H. pylori*. Individuals diagnosed as *H. pylori*+ve were divided into 5 groups in our five-year follow-up according to NAFLD status as follows: people with NAFLD (37/206, 18.0%), participants without NAFLD (95/206, 46.1%), patients with NAFLD recovering to without (19/206, 9.2%), people from without NAFLD to with (6/206, 2.9%), and irregular changes between the onset and recovery of NAFLD within 5 years (49/206, 23.8%). In the same way, patients diagnosed as *H. pylori*-ve were also divided into five groups as below: patients with NAFLD (73/469, 15.6%), people without NAFLD (207/469, 44.1%), patients with NAFLD recovering to without (48/469, 10.2%), people from without

NAFLD to with (33/469, 7.0%), and the morbidity and rehabilitation of NAFLD were irregular (108/469, 20.7%). Statistical results are shown in Table 3. We found that the recovery rate of NAFLD in the *H. pylori*+ve group was lower than that in the control group (6/206; 2.9% versus 33/469; 7.0%) ($p < 0.001$), indicating that *H. pylori* infection significantly decreased the cure of NAFLD, while there were no statistical differences in the recovery of NAFLD and *H. pylori* infection between the participants within 5 years ($p = 0.36$).

4. Discussion

In this cohort study of the association between *H. pylori* infection and the risk of incident NAFLD, we found that the infection rate of *H. pylori* was observed to gradually decrease from 2013 to 2017 in the patient population (Figure 2). The continuous infection rate of *H. pylori* for 5 years was 30.5% (Table 1), which is lower than that for the general Chinese population (39%-48%), possibly due to living in crowded conditions and low socioeconomic status of the participants [21, 22]. In terms of gender, women have lower rates of *H. pylori* infection than men, Chen et al. observed that female is an independent protective factor for *H. pylori* infection [23]; similar results were also observed in our study (Table 2), which could be due to the gender-related hormonal differences. *H. pylori* infection can cause Mets [24, 25]. A cohort study on 17,028 participants showed that lipid metabolism markers, such as LDL-C, HDL-C, and TG, were significantly associated with *H. pylori* [16, 26], which is consistent with our finding that elevated LDL-C and TG but decreased HDL-C were observed in *H. pylori*+ve individuals. This may be because *H. pylori* infection can enhance oxidative stress, subsequently affecting the insulin signaling pathway through multiple ways, such as inhibiting the activation of fatty acyl inositol 3 kinase p85 subunits, preventing the transport of glucose transporter-4 from the vesicle to the plasma membrane, and downregulating the expression of glucose transporter protein-4, thereby leading to IR and eventually causing dyslipidemia and glucose metabolism disorders [27, 28]. It is worth noting that this study showed that TG, uric acid levels, and diabetes are significantly associated with *H. pylori* infection in 205 patients [22], consistent with our findings. Still, urea nitrogen, cholesterol, ALT, and total protein metabolism abnormalities are not associated with *H. pylori* infection ($p > 0.05$) (Table 2). More studies are needed to confirm these results further.

NAFLD is an acquired metabolism-related liver injury, related to an increased risk of chronic kidney disease, type 2 diabetes, and cardiovascular disease [5]. There has been an intensive debate on the associations and causalities between *H. pylori* and NAFLD in recent years. A retrospective study on 3,663 patients in South Korea demonstrated that *H. pylori* infection was a risk factor for NAFLD [29]. A similar conclusion was reported in another study based on biopsy analysis from patients with *H. pylori* infection [30]. This may be caused by *H. pylori*-induced interleukin-1 (IL-1), IL-6, tumor necrosis factor, interferon, and c-




FIGURE 1: Diagram of patients included in the study. ΔOB: delta over baseline; NAFLD: nonalcoholic fatty liver disease.

TABLE 1: Characteristics of all participants based on *H. pylori* infection.

	Mean ± SD
Age (years)	54.7 ± 8.6 (years)
ALT (U/L)	19.8 ± 11.9 (U/L)
Total protein (mmol/L)	72.3 ± 4.0 (mmol/L)
Cholesterol (mmol/L)	4.8 ± 0.9 (mmol/L)
TG (mmol/L)	1.5 ± 0.1 (mmol/L)
HDL-C (mmol/L)	1.3 ± 0.3 (mmol/L)
LDL-C (mmol/L)	3.2 ± 0.8 (mmol/L)
Urea nitrogen (mmol/L)	5.4 ± 1.4 (mmol/L)
Uric acid (mmol/L)	336 ± 79.1 (mmol/L)
Postprandial blood sugar (mmol/L)	6.9 ± 2.2 (mmol/L)
Fasting plasma glucose (mmol/L)	5.2 ± 1.0 (mmol/L)
<i>H. pylori</i> +ve	206 (30.5%) (mmol/L)
NAFLD	110 (16.3%)

reactive protein, which can cause hepatocyte damage; another possible reason is that *H. pylori* infection can increase intestinal permeability and facilitate the passage of

bacterial toxins through the portal vein to the liver [31, 32]. It is worth noting that some inconsistent findings were also reported. Studies in South Korea and Japan showed that body mass index, smoking, and c-reactive protein concentration were risk factors for NAFLD, but *H. pylori* infection did not increase NAFLD risk [33, 34]. Our study supported the first point and showed that NAFLD had a higher rate in *H. pylori*-positive patients ($p < 0.05$) (Tables 2 and 3). NAFLD is more difficult to recover to normal under *H. pylori* infection situation ($p < 0.001$) (Table 3). These results may vary depending on participants' lifestyles, diet, and physical activity. Additionally, the host's health, the intensity of inflammatory response, autoimmune response, and antioxidant protection are all related to *H. pylori* infection [15, 35]. Moreover, different *H. pylori* detection technologies and specimen locations may lead to significant differences in test results [36, 37]. However, there was no significant statistical difference in the incidence of new NAFLD within five years ($p = 0.36$) (Table 3), which may be due to the insufficient follow-up time or small sample size.

NAFLD, which is currently renamed to metabolic- (dysfunction) associated fatty liver disease (MAFLD) [38], is closely associated with metabolic syndrome (Mets). There is a big overlap between NAFLD and Mets [39, 40]. NAFLD




FIGURE 2: The trend of H. pylori infection rate in five years.

TABLE 2: Characteristics of categorical variables broken down by H. pylori status (统计占比).

	Total Number	H. pylori (+) Number	H. pylori (-) Number	p value
Gender (male/female)	506/169	152/54	354/115	0.026*
Postprandial blood glucose (mmol/L)	47 (7.0%)	17 (8.3%)	30 (6.4%)	<0.001*
ALT (U/L)	2 (0.3%)	1 (0.5%)	1 (0.2%)	0.518
Total protein (mmol/L)	671 (99.4%)	203 (98.5%)	468 (99.8)	0.087
Cholesterol (mmol/L)	152 (2%)	4 (19.4%)	11 (2.3%)	0.497
TG (mmol/L)	59 (8.7%)	20 (9.7%)	39 (8.3%)	<0.001*
HDL-C (mmol/L)	30 (4.4%)	14 (6.8%)	16 (3.4%)	<0.001*
LDL-C (mmol/L)	341 (50.5%)	106 (51.5%)	235 (50.1%)	<0.001*
Urea nitrogen (mmol/L)	2 (0.3%)	1 (0.5%)	1 (0.2%)	0.518
Uric acid (mmol/L)	34 (5.0%)	14 (6.8%)	20 (4.3%)	<0.001*
Fasting plasma glucose (mmol/L)	20 (3.0%)	7 (3.4%)	13 (2.8%)	<0.001*
NAFLD	110 (16.3%)	37 (18%)	73 (15.6%)	<0.001*

* represents that the index was statistically significant among the participants with H. pylori+ve.




FIGURE 3: Correlation between H. pylori and NAFLD every year; * means p is less than 0.05.

TABLE 3: The relationship between the occurrence and recovery of NAFLD and H. pylori.

Variable	H. pylori (+)	H. pylori (-)	p value
Positive to negative	19 (9.2%)	48 (10.2%)	
Positive	37 (18.0%)	73 (15.6%)	0.36
Negative to positive	6 (2.9%)	33 (7.0%)	
Negative	95 (46.1%)	207 (44.1%)	<0.001*

* means p is less than 0.05.

is mutually and bidirectionally linked with Mets, and it is both the cause and the consequence of Mets [36]. These conditions share similar pathophysiological mechanisms and risk factors [41–43]. More specifically, IR and inflammation link these conditions to each other. Along with IR, some other pathophysiological mechanisms, e.g., disordered lipid metabolism, increased oxidative stress, and inflammation, link NAFLD to Mets [44]. Among the metabolic variables, lipid metabolism markers, such as LDL-C, HDL-C, and the combination of LDL-C, HDL-C, and triglycerides, were significant mediators of the association between H. pylori infection and NAFLD [23]. It is worth noting that H. pylori infection may increase oxidative stress and may be linked to chronic inflammation, IR, and disturbance of lipid metabolism [10, 22, 27, 45]. Besides, the Mets risks that H. pylori are known to cause are most of all a consequence of insulin resistance and its comorbidities, which, in turn, are closely associated with NAFLD. Thereby, eradication of H. pylori may be an important step to prevent Mets and reduce NAFLD. The exact mechanism linking H. pylori infection and NAFLD to Mets needs to be further studied in more detail. However, the limitations of the present study must be noted: this is a retrospective analysis of our hospital database without further adjustment for other factors such as age, economic status, and living environment, which may affect this study's results. Despite the limitations, our study has some advantages. To our knowledge, our study is the first to follow up NAFLD for five consecutive years in China, further confirming the relationships between H. pylori infection and NAFLD.

In conclusion, H. pylori are the highway for Mets and NAFLD, resulting in a serious public health problem worldwide. Therefore, patients infected with H. pylori need to be highly vigilant and timely to identify NAFLD. From a long-range point of view, it is of utmost importance to eradicate H. pylori infection in subjects who may be at increased risk for future Mets or NAFLD, which may help prevent Mets and NAFLD and therefore provides novel insights for effective prevention and treatment of NAFLD.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflicts of interest related to the manuscript.

Authors' Contributions

Xia-Xia Zhao participated in the article design and the whole article writing. Ming-Hao Liu participated in the design of the article. Rui-ling Wang and Xiao-jun Huang revised the manuscript.

Acknowledgments

The author would like to thank all people who contributed to this article. The research was funded by the special fund project for doctoral training program of Lanzhou University Second Hospital (Item Number: PR5124007) and Cuiying Scientific and Technology Innovation Program of "Lanzhou University Second Hospital" (Item Number: 2020QN-12).

References

- [1] J. Kountouras, A. Papaefthymiou, M. Doulberis, and S. A. Polyzos, "Influence of Helicobacter pylori-connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk," *Liver international: official journal of the International Association for the Study of the Liver*, vol. 40, no. 2, pp. 475–476, 2020.
- [2] J. Kountouras, M. Doulberis, A. Papaefthymiou et al., "A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection," *Annals of the New York Academy of Sciences*, vol. 1452, no. 1, pp. 12–17, 2019.
- [3] J. Kountouras, S. A. Polyzos, M. Doulberis et al., "Potential impact of _Helicobacter pylori_-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis," *Metabolism: clinical and experimental*, vol. 87, pp. 18–24, 2018.
- [4] M. Zamani, F. Ebrahimitabar, V. Zamani et al., "Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection," *Alimentary Pharmacology & Therapeutics*, vol. 47, no. 7, pp. 868–876, 2018.
- [5] J. K. Y. Hooi, W. Y. Lai, W. K. Ng et al., "Global Prevalence of _Helicobacter pylori_ Infection: Systematic Review and Meta-Analysis," *Gastroenterology*, vol. 153, no. 2, pp. 420–429, 2017.
- [6] S. A. Polyzos, J. Kountouras, and C. S. Mantzoros, "_Helicobacter pylori_ infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?," *Metabolism: clinical and experimental*, vol. 96, pp. iii–iiv, 2019.
- [7] S. A. Polyzos and J. Kountouras, "Helicobacter pylori infection and nonalcoholic fatty liver disease: time for large clinical trials evaluating eradication therapy," *Helicobacter*, vol. 24, no. 3, article e12588, 2019.
- [8] V. W.-S. Wong, W. C.-W. Chu, G. L.-H. Wong et al., "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography," *Gut*, vol. 61, no. 3, pp. 409–415, 2012.

- [9] F. Nascimbeni, R. Pais, S. Bellentani et al., "From NAFLD in clinical practice to answers from guidelines," *Journal of Hepatology*, vol. 59, no. 4, pp. 859–871, 2013.
- [10] O. Cai, Z. Huang, M. Li, C. Zhang, F. Xi, and S. Tan, "Association between *Helicobacter pylori* infection and nonalcoholic fatty liver disease: a single-center clinical study," *Gastroenterology Research and Practice*, vol. 2018, Article ID 8040262, 6 pages, 2018.
- [11] F. Francois, J. Roper, N. Joseph et al., "The effect of *H. pylori* eradication on meal-associated changes in plasma ghrelin and leptin," *BMC gastroenterology*, vol. 11, no. 1, 2011.
- [12] D. Kibru, B. Gelaw, A. Alemu, and Z. Addis, "Helicobacter pylori infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia," *Ethiopia. BMC infectious diseases*, vol. 14, no. 1, 2014.
- [13] A. M. Alzahrani, A. A. Al Zaidi, and S. M. Alzahrani, "Association between type 2 diabetes mellitus and *Helicobacter pylori* infection among Saudi patients attending National Guard Primary Health Care Centers in the Western Region, 2018," *Journal of Family & Community Medicine*, vol. 27, no. 1, pp. 8–14, 2020.
- [14] H.-M. Shih, T.-Y. Hsu, C.-Y. Chen et al., "Analysis of patients with *Helicobacter pylori* infection and the subsequent risk of developing osteoporosis after eradication therapy: a nationwide population-based cohort study," *PLoS One*, vol. 11, no. 9, article e0162645, 2016.
- [15] H. H. Lin, C. Y. Huang, and L. C. Hwang, "Association between metabolic syndrome and osteoporosis in Taiwanese middle-aged and elderly participants," *Archives of Osteoporosis*, vol. 13, no. 1, p. 48, 2018.
- [16] T. J. Kim, D. H. Sinn, Y. W. Min et al., "A cohort study on *Helicobacter pylori* infection associated with nonalcoholic fatty liver disease," *Journal of Gastroenterology*, vol. 52, no. 11, pp. 1201–1210, 2017.
- [17] M.-Y. Xu, J.-H. Ma, J. Du et al., "Nonalcoholic fatty liver disease is associated with *Helicobacter pylori* infection in north urban Chinese: a retrospective study," *Gastroenterology research and practice*, vol. 2020, Article ID 9797841, 6 pages, 2020.
- [18] L. Ning, R. Liu, X. Lou et al., "Association between *Helicobacter pylori* infection and nonalcoholic fatty liver disease: a systematic review and meta-analysis," *European Journal of Gastroenterology & Hepatology*, vol. 31, no. 7, pp. 735–742, 2019.
- [19] J. G. Fan, L. Wei, and H. Zhuang, "Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)," *Journal of Digestive Diseases*, vol. 20, no. 4, pp. 163–173, 2019.
- [20] T.-P. Chen, H.-F. Hung, M.-K. Chen et al., "Helicobacter pylori infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study," *Helicobacter*, vol. 20, no. 3, pp. 184–191, 2015.
- [21] A. C. Gagliardi, M. H. Miname, and R. D. Santos, "Uric acid: a marker of increased cardiovascular risk," *Atherosclerosis*, vol. 202, no. 1, pp. 11–17, 2009.
- [22] W. Yang and C. Xuan, "Influence of *Helicobacter pylori* infection on metabolic syndrome in old Chinese people," *Gastroenterology Research and Practice*, vol. 2016, Article ID 6951264, 2016.
- [23] B. Longo-Mbenza, J. Nkondi Nsenga, and N. D. Vangu, "Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by *Helicobacter pylori* infection and treated by antibiotics," *International Journal of Cardiology*, vol. 121, no. 3, pp. 229–238, 2007.
- [24] E. Isiktas Sayilar, B. Celik, and S. Dumlu, "Relationship between *Helicobacter pylori* infection and metabolic syndrome," *The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology*, vol. 26, no. 6, pp. 468–473, 2015.
- [25] D. W. Shin, H. T. Kwon, J. M. Kang et al., "Association between metabolic syndrome and *Helicobacter pylori* infection diagnosed by histologic status and serological status," *Journal of Clinical Gastroenterology*, vol. 46, no. 10, pp. 840–845, 2012.
- [26] M.-M. Zhao, J. Krebs, X. Cao et al., "Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey," *BMC Infectious Diseases*, vol. 19, no. 1, p. 157, 2019.
- [27] Q. Xie, M. Pan, R. Huang et al., "Short communication: Modulation of the small intestinal microbial community composition over short-term or long-term administration with *Lactobacillus plantarum* ZDY2013," *Journal of Dairy Science*, vol. 99, no. 9, pp. 6913–6921, 2016.
- [28] R. Eid and S. F. Moss, "Helicobacter pylori infection and the development of gastric cancer," *The New England Journal of Medicine*, vol. 346, no. 1, pp. 65–67, 2002.
- [29] M. J. Blaser, G. I. Perez-Perez, and H. Kleanthous, "Infection with *Helicobacter pylori* strains possessing *cagA* is associated with an increased risk of developing adenocarcinoma of the stomach," *Cancer Research*, vol. 55, no. 10, pp. 2111–2115, 1995.
- [30] B.-G. Zhou, H.-J. Yang, W. Xu, K. Wang, P. Guo, and Y.-W. Ai, "Association between *Helicobacter pylori* infection and nonalcoholic fatty liver disease: a systematic review and meta-analysis of observational studies," *Helicobacter*, vol. 24, no. 3, article e12576, 2019.
- [31] O. Eslami, M. Shahraki, T. Shahraki, and H. Ansari, "Association of *Helicobacter pylori* infection with metabolic parameters and dietary habits among medical undergraduate students in southeastern of Iran," *Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences*, vol. 22, no. 1, p. 12, 2017.
- [32] A. C. Manolakis, E. K. Tiaka, A. N. Kapsoritakis et al., "Increased fetuin A levels in *Helicobacter pylori* infection: a missing link between *H. pylori* and insulin resistance?," *Diabetologia*, vol. 54, no. 2, pp. 472–474, 2011.
- [33] L.-W. Chen, S.-F. Kuo, C.-H. Chen, C.-H. Chien, C.-L. Lin, and R.-N. Chien, "A community-based study on the association between *Helicobacter pylori* infection and obesity," *Scientific Reports*, vol. 8, no. 1, 2018.
- [34] J. Roper, F. Francois, P. L. Shue et al., "Leptin and ghrelin in relation to *Helicobacter pylori* status in adult males," *The Journal of Clinical Endocrinology and Metabolism*, vol. 93, no. 6, pp. 2350–2357, 2008.
- [35] A. Izzotti, P. Durando, F. Ansaldi, F. Gianiorio, and A. Pulliero, "Interaction between *Helicobacter pylori*, diet, and genetic polymorphisms as related to non-cancer diseases," *Mutation Research*, vol. 667, no. 1-2, pp. 142–157, 2009.
- [36] F. Yang, Y. L. Xu, and R. F. Zhu, "Helicobacter pylori infection and the risk of colorectal carcinoma: a systematic review and meta-analysis," *Minerva Medica*, vol. 110, no. 5, pp. 464–470, 2019.

- [37] F. Wang, M. Y. Sun, S. L. Shi, and Z. S. Lv, "Helicobacter pylori infection and normal colorectal mucosa-adenomatous polyp-adenocarcinoma sequence: a meta-analysis of 27 case-control studies," *Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland*, vol. 16, no. 4, pp. 246–252, 2014.
- [38] M. Eslam, P. N. Newsome, S. K. Sarin et al., "A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement," *Journal of Hepatology*, vol. 73, no. 1, pp. 202–209, 2020.
- [39] A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilainen, and H. Yki-Jarvinen, "Liver fat in the metabolic syndrome," *The Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 9, pp. 3490–3497, 2007.
- [40] M. V. Machado and H. Cortez-Pinto, "Non-alcoholic fatty liver disease: what the clinician needs to know," *World Journal of Gastroenterology*, vol. 20, no. 36, pp. 12956–12980, 2014.
- [41] A. Lonardo, S. Ballestri, G. Marchesini, P. Angulo, and P. Loria, "Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome," *Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, vol. 47, no. 3, pp. 181–190, 2015.
- [42] N. Stefan, K. Kantartzis, and H. U. Haring, "Causes and metabolic consequences of fatty liver," *Endocrine Reviews*, vol. 29, no. 7, pp. 939–960, 2008.
- [43] E. Fabbrini, S. Sullivan, and S. Klein, "Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications," *Hepatology (Baltimore, Md)*, vol. 51, no. 2, pp. 679–689, 2010.
- [44] N. C. Leite, C. A. Villela-Nogueira, C. R. Cardoso, and G. F. Salles, "Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment," *World Journal of Gastroenterology*, vol. 20, no. 26, pp. 8377–8392, 2014.
- [45] A. R. Khoshdel and R. Eshtiaghi, "Assessment of arterial stiffness in metabolic syndrome related to insulin resistance in apparently healthy men," *Metabolic Syndrome and Related Disorders*, vol. 17, no. 2, pp. 90–96, 2019.